Skip to content

Study · Not a test of the peptide alone · 2002

9 results

The impact of cranial irradiation on GH responsiveness to GHRH plus GH-releasing peptide-6.

Popovic V, Pekic S, Golubicic I, Doknic M, Dieguez C, Casanueva FF

The Journal of clinical endocrinology and metabolism1 May 2002Cited by 18 (Europe PMC)

PMID11994347 (opens in a new tab)DOI10.1210/jcem.87.5.8485 (opens in a new tab)PepBankPUB-11994347
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Sermorelin aloneObservational studyOther

    Of 22 adults who had cranial radiation, twelve were GH-deficient on both the insulin tolerance test and the GHRH plus GHRP-6 test.

    In plain wordsAfter head radiation, twelve of 22 adults had low growth hormone on both of two stimulation tests.

    Peptide
    Sermorelin
    Outcome
    Not applicableGH deficiency by ITT and GHRH+GHRP-6 tests
    Study

    n = 22

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Twelve out of 22 irradiated patients were GH-deficient (GHD) with both tests.
    1 context sentence
    Summary · context
    The GH-releasing effect of GHRH plus GH secretagogue [GH-releasing peptide (GHRP)-6] (GHRH+GHRP-6) was studied in 22 adult patients (age, 23.2 +/- 1.4 yr; 8 female and 14 male; mean body mass index, 22.6 +/- 0.7 kg/m(2)) who received cranial radiation for primary brain tumor distant from hypothalami…

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  2. 02HumanNot a test of GHRP-6 aloneObservational studyOther

    In 22 adults who received cranial radiation, twelve were GH-deficient with both the insulin tolerance test and the GHRH plus GHRP‑6 test.

    In plain wordsIn adults treated with cranial radiation, twelve of 22 showed low growth hormone responses on both the insulin test and the GHRH plus GHRP‑6 test.

    Peptide
    GHRP-6
    Outcome
    Not applicableGH deficiency diagnosed with both tests
    Study

    n = 22

    Comparator
    Insulin tolerance test
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Twelve out of 22 irradiated patients were GH-deficient (GHD) with both tests.
    1 context sentence
    Summary · context
    The GH-releasing effect of GHRH plus GH secretagogue [GH-releasing peptide (GHRP)-6] (GHRH+GHRP-6) was studied in 22 adult patients (age, 23.2 +/- 1.4 yr; 8 female and 14 male; mean body mass index, 22.6 +/- 0.7 kg/m(2)) who received cranial radiation for primary brain tumor distant from hypothalami…

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  3. 03HumanNot a test of Sermorelin aloneObservational studyEfficacy outcome

    In 9 irradiated patients, mean peak GH after the GHRH plus GHRP-6 test was 6.2 microg/liter, in the severe GH-deficiency range.

    In plain wordsIn 9 patients after head radiation, the combined GHRH plus GHRP-6 test gave a low growth hormone peak, in the severe deficiency range.

    Peptide
    Sermorelin
    Outcome
    Not applicablePeak GH after GHRH+GHRP-6 test
    Study

    n = 9

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Mean peak GH
    6.2 microg/liter
    GHRH+GHRP-6 test, 9 irradiated patients

    Source sentences

    Summary
    In 9 irradiated patients, in whom ITT was performed as well, mean peak GH after the GHRH+GHRP-6 test was 6.2 +/- 0.8 microg/liter, which is considered as severe GHD, according to our own cut-off for the test (peak GH < 10 microg/liter).
    1 context sentence
    Summary · context
    The GH-releasing effect of GHRH plus GH secretagogue [GH-releasing peptide (GHRP)-6] (GHRH+GHRP-6) was studied in 22 adult patients (age, 23.2 +/- 1.4 yr; 8 female and 14 male; mean body mass index, 22.6 +/- 0.7 kg/m(2)) who received cranial radiation for primary brain tumor distant from hypothalami…

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  4. 04HumanNot a test of GHRP-6 aloneObservational studyOther

    In nine irradiated adults, mean peak GH after the combined GHRH plus GHRP‑6 test was 6.2 µg/liter, in the range of severe GH deficiency.

    In plain wordsIn nine adults treated with cranial radiation, the GHRH plus GHRP‑6 test gave a low mean growth hormone peak.

    Peptide
    GHRP-6
    Outcome
    Not applicablePeak GH after GHRH plus GHRP-6 test
    Study

    n = 9

    Comparator
    Insulin tolerance test
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Mean peak GH
    6.2 µg/liter
    GHRH+GHRP-6 test, 9 irradiated patients

    Source sentences

    Summary
    In 9 irradiated patients, in whom ITT was performed as well, mean peak GH after the GHRH+GHRP-6 test was 6.2 +/- 0.8 microg/liter, which is considered as severe GHD, according to our own cut-off for the test (peak GH < 10 microg/liter).
    1 context sentence
    Summary · context
    The GH-releasing effect of GHRH plus GH secretagogue [GH-releasing peptide (GHRP)-6] (GHRH+GHRP-6) was studied in 22 adult patients (age, 23.2 +/- 1.4 yr; 8 female and 14 male; mean body mass index, 22.6 +/- 0.7 kg/m(2)) who received cranial radiation for primary brain tumor distant from hypothalami…

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  5. 05HumanNot a test of Sermorelin aloneObservational studyOther

    One irradiated patient was diagnosed as GH-deficient only with the combined test, because the ITT was contraindicated by epilepsy.

    In plain wordsOne patient after head radiation could be tested for growth hormone deficiency only with the combined GHRH plus GHRP-6 test, because of epilepsy.

    Peptide
    Sermorelin
    Outcome
    Not applicableGHD diagnosed only with the combined test
    Study

    n = 1

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    One irradiated patient was diagnosed as GHD only with the combined test, because ITT was contraindicated because of epilepsy.
    1 context sentence
    Summary · context
    The GH-releasing effect of GHRH plus GH secretagogue [GH-releasing peptide (GHRP)-6] (GHRH+GHRP-6) was studied in 22 adult patients (age, 23.2 +/- 1.4 yr; 8 female and 14 male; mean body mass index, 22.6 +/- 0.7 kg/m(2)) who received cranial radiation for primary brain tumor distant from hypothalami…

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  6. 06HumanNot a test of Sermorelin aloneObservational studyOther

    In irradiated patients, GH responses to the GHRH plus GHRP-6 test and to the insulin tolerance test were highly concordant.

    In plain wordsIn patients after head radiation, the GHRH plus GHRP-6 test and the insulin tolerance test gave very similar growth hormone results.

    Peptide
    Sermorelin
    Outcome
    No significant changeConcordance of GH responses between ITT and GHRH+GHRP-6 test
    Study

    n: not reported in source

    Comparator
    Insulin tolerance test
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    GH responses to both tests were highly concordant
    1 context sentence
    Summary · context
    The GH-releasing effect of GHRH plus GH secretagogue [GH-releasing peptide (GHRP)-6] (GHRH+GHRP-6) was studied in 22 adult patients (age, 23.2 +/- 1.4 yr; 8 female and 14 male; mean body mass index, 22.6 +/- 0.7 kg/m(2)) who received cranial radiation for primary brain tumor distant from hypothalami…

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  7. 07HumanNot a test of Sermorelin aloneObservational studyOther

    The difference in GH peak between GH-deficient and non-deficient irradiated patients was significantly larger with the GHRH plus GHRP-6 test than with the insulin tolerance test.

    In plain wordsThe combined GHRH plus GHRP-6 test separated GH-deficient from non-deficient patients more clearly than the insulin tolerance test did.

    Peptide
    Sermorelin
    Outcome
    IncreaseGH peak difference between GHD and non-GHD patients
    Study

    n: not reported in source

    Comparator
    Insulin tolerance test
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    the differential in the GH peak concentrations between GHD and non-GHD irradiated patients was significantly larger for the GHRH+GHRP-6 test than that for the ITT.
    1 context sentence
    Summary · context
    The GH-releasing effect of GHRH plus GH secretagogue [GH-releasing peptide (GHRP)-6] (GHRH+GHRP-6) was studied in 22 adult patients (age, 23.2 +/- 1.4 yr; 8 female and 14 male; mean body mass index, 22.6 +/- 0.7 kg/m(2)) who received cranial radiation for primary brain tumor distant from hypothalami…

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  8. 08HumanNot a test of Sermorelin aloneObservational studyOther

    Two irradiated patients had discordant results, with a poor ITT response and a good GHRH plus GHRP-6 response.

    In plain wordsTwo patients after head radiation had a poor response to the insulin tolerance test but a good response to the combined GHRH plus GHRP-6 test.

    Peptide
    Sermorelin
    Outcome
    Not applicableDiscordant responses between ITT and GHRH+GHRP-6 test
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The 2 discordant responses, i.e. poor response to the ITT and good response to the GHRH+GHRP-6 test, were found in 1 hyperprolactinemic female patient and in 1 other female.
    1 context sentence
    Summary · context
    The GH-releasing effect of GHRH plus GH secretagogue [GH-releasing peptide (GHRP)-6] (GHRH+GHRP-6) was studied in 22 adult patients (age, 23.2 +/- 1.4 yr; 8 female and 14 male; mean body mass index, 22.6 +/- 0.7 kg/m(2)) who received cranial radiation for primary brain tumor distant from hypothalami…

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  9. 09HumanNot a test of GHRP-6 aloneObservational studyOther

    In irradiated adults, the GH peak difference between GH-deficient and non-deficient patients was significantly larger with the GHRH plus GHRP‑6 test than with the insulin tolerance test.

    In plain wordsIn adults treated with cranial radiation, the GHRH plus GHRP‑6 test separated low from normal growth hormone responders better than the insulin test.

    Peptide
    GHRP-6
    Outcome
    Not applicableGH peak difference between GH-deficient and non-deficient patients, by test
    Study

    n: not reported in source

    Comparator
    Insulin tolerance test
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    GH responses to both tests were highly concordant, but the differential in the GH peak concentrations between GHD and non-GHD irradiated patients was significantly larger for the GHRH+GHRP-6 test than that for the ITT.
    1 context sentence
    Summary · context
    The GH-releasing effect of GHRH plus GH secretagogue [GH-releasing peptide (GHRP)-6] (GHRH+GHRP-6) was studied in 22 adult patients (age, 23.2 +/- 1.4 yr; 8 female and 14 male; mean body mass index, 22.6 +/- 0.7 kg/m(2)) who received cranial radiation for primary brain tumor distant from hypothalami…

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:13 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.